ex vivo in vivo.
In this exclusive interview, genome editing pioneer Matthew Porteus, MD, PhD (Stanford University) looks back on some of his career milestones; discusses the recent landmark approvals of Casgevy and Lyfgenia; and shares an update on his own curative gene editing plans for sickle cell disease as the program moves from Graphite Bio to Kamau Therapeutics.The post A Story of Perseverance: An Interview with Matthew Porteus appeared first on GEN - Genetic Engineering and Biotechnology News.